Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.0
7.8
Journals
Vaccines
Special Issues
Vaccines Design and Development against Coronavirus Disease
share announcement

Vaccines Design and Development against Coronavirus Disease

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines against Infectious Diseases".

Deadline for manuscript submissions: closed (30 April 2023) | Viewed by 2375

Special Issue Editors

Prof. Dr. Suh-Chin Wu

E-Mail Website
Guest Editor
1. Department of Medical Science, Institute of Biotechnology, National Tsing Hua University, Hsinchu 30013, Taiwan
2. Adimmune Corporation, Taichung 42743, Taiwan
Interests: Immunogen design; vaccinology; influenza viruses; mucosal immunity
Special Issues, Collections and Topics in MDPI journals
Dr. Randy A. Albrecht

grade E-Mail Website1 Website2
Guest Editor
Department of Microbiology, Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Interests: vaccines; mucosal immunity; respiratory viruses; pathogenesis; animal models; biocontainment
Special Issues, Collections and Topics in MDPI journals
Dr. Wen-Chun Liu

E-Mail Website
Guest Editor
Biomedical Translation Research Center, Academia Sinica, Taipei, Taiwan
Interests: vaccines; vaccinology; infectious disease; animal models; biocontainment

Special Issue Information

Dear Colleagues,

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced coronavirus disease 2019 (COVID-19) resulted in a fast-paced global pandemic that has placed tremendous strain on public health and global economies since 2020. The rollout of COVID-19 vaccines successfully mitigated the severity and mortality of COVID-19 but did not interrupt human-to-human transmission of SARS-CoV-2. Emerging SARS-CoV-2 variants of concern (VOC) escape vaccine-induced immune responses, resulting in “breakthrough” cases of infection. To stop the impact of the COVID-19 pandemic and improve the effectiveness of licensed COVID-19 vaccines, the development of improved COVID-19 medical countermeasures, including vaccines and antivirals, are needed to block the emergence of SARS-CoV-2 VOC and future epidemics of coronavirus disease. 

In this Special Issue, we intend to gather articles covering cutting-edge technologies and future directions of novel COVID-19 or pan-coronavirus vaccines. We aim to compile a collection of articles including, but not limited to, novel next-generation COVID-19 vaccine development, investigation of immune correlates of protection induced by currently available COVID-19 vaccines, alternative strategies to COVID-19 vaccine design, e.g., formulations, administration routes, etc. In addition, we also welcome contributions that address the issues of “immune escape”, or “selective pressure” created by immunity induced by the original COVID-19 vaccine. These findings will provide precious insight to the design and development of next-generation COVID-19 vaccines or pan-coronavirus vaccines. 

Prof. Dr. Suh-Chin Wu
Dr. Randy A. Albrecht
Dr. Wen-Chun Liu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • COVID-19 Vaccine
  • SARS-CoV-2 variants of concern
  • adjuvants
  • mucosal immunity
  • immune escape
  • immunobridging and correlates of protection
  • pan-coronavirus vaccine

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 5317 KiB  
Article
Tracking B Cell Memory to SARS-CoV-2 Using Rare Cell Analysis System
by Dong-Yan Tsai, Chun-Hung Wang, Perry G. Schiro, Nathan Chen and Ju-Yu Tseng
Vaccines 2023, 11(4), 735; https://doi.org/10.3390/vaccines11040735 - 26 Mar 2023
Viewed by 1743
Abstract
Rapid mutations within SARS-CoV-2 are driving immune escape, highlighting the need for in-depth and routine analysis of memory B cells (MBCs) to complement the important but limited information from neutralizing antibody (nAb) studies. In this study, we collected plasma samples and peripheral blood [...] Read more.
Rapid mutations within SARS-CoV-2 are driving immune escape, highlighting the need for in-depth and routine analysis of memory B cells (MBCs) to complement the important but limited information from neutralizing antibody (nAb) studies. In this study, we collected plasma samples and peripheral blood mononuclear cells (PBMCs) from 35 subjects and studied the nAb titers and the number of antigen-specific memory B cells at designated time points before and after vaccination. We developed an assay to use the MiSelect R II System with a single-use microfluidic chip to directly detect the number of spike-receptor-binding domain (RBD)-specific MBCs in PBMCs. Our results show that the number of spike-RBD-specific MBCs detected by the MiSelect R II System is highly correlated with the level of nAbs secreted by stimulated PBMCs, even 6 months after vaccination when nAbs were generally not present in plasma. We also found antigen-specific cells recognizing Omicron spike-RBD were present in PBMCs from booster vaccination of subjects, but with a high variability in the number of B cells. The MiSelect R II System provided a direct, automated, and quantitative method to isolate and analyze subsets of rare cells for tracking cellular immunity in the context of a rapidly mutating virus. Full article
(This article belongs to the Special Issue Vaccines Design and Development against Coronavirus Disease)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop